5/17/2017 Print View

# Enforcement Report - Week of May 17, 2017

**Class II Drugs Event** 

Event ID: 77109

Status: Ongoing

Recall Initiation Date:

04/24/2017

Center Classification Date:

05/11/2017

Recalling Firm:

Teva Pharmaceuticals USA 1090 Horsham Rd

North Wales PA United States

Distribution Pattern:

Nationwide

**Associated Products** 

Product Description:

Clozapine Tablets USP, 25 mg, 100-count bottle (NDC 0093-4359-01), 500- count bottle (NDC 0093-4359-05), 100 Unit Dose Blisters per carton (NDC 0093-4359-93), Individual Blister Pack (NDC 0093-4359-19), Rx Only,

Product Type:

Voluntary / Mandated:

Voluntary: Firm Initiated

Initial Firm Notification of Consignee or Public:

Drugs Date Terminated:

Letter

Manufactured By: Teva Pharmaceutical Industries Ltd., Jerusalem, 9777600, Israel

Product Quantity:

Reason for Recall:

Microbial Contamination of Non-Sterile Products

Recall Number:

D-0705-2017

Code Information:

100 (NDC 0093-4359-01) and 500 count bottles (NDC 0093-4359-05)- Lot # 07C160; Exp. 03/18 100 Unit Dose Blisters/Carton (NDC 0093-4359-93) and Individual Blister Pack (NDC 0093-4359-19) - Lot # 07C160A; Exp. 03/

**Product Type:** 

Voluntary / Mandated:

Voluntary: Firm Initiated

Initial Firm Notification of Consignee or Public:

Drugs Date Terminated:

**Class II Drugs Event** 

Event ID: 77169

Ongoing

Recall Initiation Date:

04/28/2017

Center Classification Date:

Recalling Firm: PAR Sterile Products LLC

870 Parkdale Rd Rochester MI United States

Distribution Pattern:

Nationwide in the USA

**Associated Products** 

Product Description: Buprenorphine HCI Injection, 0.3 mg/mL, 1 mL Single Dose Vial (NDC 42023-179-01), packaged in 1 mL x 5 Single Dose Vials per carton (NDC 42023-179-05), Rx Only, Distributed by: Par Pharmaceuticals Companies, Inc., Spring Valley, NY 10977.

Product Quantity:

122,469 cartons

Crystallization: due to the presence of white, crystalline particulates, adhered to the side and bottom of the glass vials, which are comprised of principally dextrose and the buprenorphine active component.

Recall Number:

D-0698-2017

Code Information:

Lot #: 821102, 821103, Exp 01/18; 821104, 821106, 821107, Exp 02/18; 821108, Exp 03/18; 821884, 821885, Exp 07/18; 821886, 821887, Exp 08/18; 822767, Exp 09/18; 824183, Exp 10/18

**Class III Drugs Event** 

Event ID:

76819

Status: Ongoing

Recall Initiation Date:

Center Classification Date:

05/10/2017

Recalling Firm:

270 Prospect Plains Rd

Sun Pharmaceutical Industries, Inc.

Voluntary: Firm Initiated

Voluntary / Mandated:

**Product Type:** 

Date Terminated:

Initial Firm Notification of Consignee or Public: Letter

5/17/2017 Print View

### **Distribution Pattern:**

Nationwide in the USA and Puerto Rico

### **Associated Products**

### Product Description:

Olanzapine Tablets, 2.5 mg, 1000-count bottles, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat India, NDC 62756-551-18.

### Product Quantity

60 bottles

### Reason for Recall:

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities)

### Recall Numbe

D-0699-2017

#### Code Information:

Lot #: JKP2751A, Exp 05/17; JKR5048A, Exp 04/18

#### Product Description:

Olanzapine Tablets, 7.5 mg, packaged in a) 30-count bottles (NDC 62756-553-83), b) 100-count bottles (NDC 62756-553-88), and c) 1000-count bottles (NDC 62756-553-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.

#### Product Quantity

6,138 bottles

### Reason for Recall:

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities)

#### Recall Numbe

D-0700-2017

### Code Information:

Lot #: a) JKP3150B, Exp 06/17, JKR5749A, Exp 06/18; b) JKP2757A, Exp 05/17, JKP3149A, JKP3150A, Exp 06/17, JKR5049A, Exp 04/18; c) JKP2758B, Exp 05/17

#### Product Description

Olanzapine Tablets, 10 mg, packaged in a) 30-count bottles (NDC 62756-554-83), b) 100-count bottles (NDC 62756-554-88), and c) 1000-count bottles (NDC 62756-554-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India, NDC 62756-551-18.

### Product Quantity:

38,316 bottles

### Reason for Recall:

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities)

#### Recall Number:

D-0701-2017

### Code Information:

Lot #: a) JKP1354A, Exp 03/17, JKP2746A, Exp 06/17, JKR5751A, Exp 04/18; b) JKP1355A, Exp 03/17, JKP2738A, JKP3145A, Exp 06/17, JKR5476A, Exp 04/18; c) JKP1353A, Exp 03/17, JKP3146A, JKP2746B, Exp 06/17

**Product Type:** 

**Date Terminated:** 

Voluntary / Mandated:

Voluntary: Firm Initiated

Initial Firm Notification of Consignee or Public:

Drugs

Letter

### Product Description

Olanzapine Tablets, 20 mg, packaged in a) 30-count bottles (NDC 62756-556-83), b) 100-count bottles (NDC 62756-556-88), and c) 1000-count bottles (NDC 62756-556-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.

# Product Quantity:

14,784 bottles

# Reason for Recall:

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).

# Recall Number

D-0702-2017

# Code Information:

Lot #: a) JKR5759A, Exp 04/18; b) JKP0943A, Exp 04/17, JKR5520A, Exp 04/18; c) JKP0988A, Exp 04/17

# **Class III Drugs Event**

Event ID:

76871

Status:

Ongoing

Recall Initiation Date:

03/28/2017

Center Classification Date: 05/11/2017

\_\_\_\_\_

Recalling Firm: Teva Pharmaceuticals USA

1090 Horsham Rd

North Wales PA United States

Distribution Pattern: Nationwide

# **Associated Products**

# Product Description:

PrednisoLONE Oral Solution USP, 15 mg/5mL, alcohol content: 5%(v/v) 240 mL bottle, Rx Only, Manufactured in Canada By: CONTRACT PHARMACEUTICALS LIMITED CANADA, Ontario, Canada, L5N 6L6, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-6118-87

# Product Quantity:

49,089 bottles

# Reason for Recall:

Failed Stability Specifications

# Recall Number:

D-0703-2017